MRSA is responsible for about 19,000 deaths and 368,000 hospitalizations in the U.S. each year, with annual costs of up to $4.2 billion to treat it, according to Pew Health Initiatives. The staph infection is resistant to most commonly used antibiotics. It’s just one of the hospital-acquired infections that hospitals are combating. A life science startup has raised fresh capital to advance the development of therapeutics to treat bacterial infections from MRSA to salmonella.
The Malvern, Pa.-based VenatoRx Pharmaceuticals was formed by Christopher Burns, president and chief scientific officer; Daniel Pevear, vice president of biology and grant development; and Luigi Xerri, chief development officer. They were part of the executive team at Protez, a company that developed antibiotics to combat infections, including hospital-acquired infections.
VenatoRx is picking up where the discovery and development of innovative antibacterial treatments at Protez left off. Novartis acquired Protez in a $400 million acquisition in 2008, including $100 million up front. But in 2010 the technology was shelved and its staff laid off.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The biotech startup raised $3.4 million, according to a Form D document filed with the U.S. Securities and Exchange Commission. According to the filing, the biotech has nearly 60 investors
In 2010, VenatoRx won a $21.2 million grant from the National Institutes of Health for its proposal to treat food- and water-borne infections.
Several different life science companies have taken different approaches to combating MRSA:
- MedDev’s treatment to reduce MRSA nasal colonization is under development.
- AstraZeneca developed an antibiotic to fight MRSA called Zinfor. It was approved for the EU earlier this year.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Other companies are developing ways to diagnose MRSA faster:
- FCubed LLC has produced a portable microfluidics device that can detect the presence of MRSA in fluid samples in less than an hour.
- Molecular Detection’s Detect Ready MRSA diagnostic test to identify MRSA carriers was been cleared by the EU.
Hospital ICUs have also found some success in the way they identify patients with the infection and clean them, according to a study published in the New England Journal of Medicine.
